A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas (Protocol 102)
This study is ongoing, but not recruiting participants.
Sponsor:
University of Alabama at Birmingham
Collaborators:
Children's Hospital Boston
Children's Hospital of Philadelphia
Children's Research Institute
Children's Hospital Medical Center, Cincinnati
University of Chicago
University of Utah
Washington University School of Medicine
Information provided by (Responsible Party):
Bruce Korf, MD, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00634270
First received: February 20, 2008
Last updated: April 25, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is ongoing, but not recruiting participants. |
|---|---|
| Estimated Study Completion Date: | August 2013 |
| Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |